This is a prospective, gold standard observational trial designed to enroll consecutive, consenting ovarian cancer patients for the purpose of determining sensitivity of an assay that detects circulating tumor DNA. This observational pilot trial will also be used to examine the genetic variants/mutations present in the tumor tissue DNA.

Inclusion Criteria:

Case Group

• Patients with ovarian cancer undergoing surgery (all stages)
• Over 18 years old

Control Group

• Patients with a benign gynecological condition undergoing surgery
• Over 18 years old

Exclusion Criteria:

• Previous cancer diagnosis (all)
• Radiation therapy before surgical treatment
• Bone marrow transplant
• Chemotherapy before surgical treatment
• Invasive procedure resulting in damage to tissue (e.g., surgery, biopsy, thermal ablation) in the 7 days prior to baseline (pre-surgical) blood collection

Women undergoing surgery as part of the treatment plan for ovarian cancer or a benign gynecological neoplasm.